Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
NCT01606982 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2017-02-17
Summary
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
Conditions
Interventions
- DRUG
-
MDV3100
oral
Sponsors & Collaborators
-
Medivation, Inc.
collaborator INDUSTRY -
Astellas Pharma Global Development, Inc.
lead INDUSTRY
Eligibility
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide
NCT01091103 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
NCT01547299 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
NCT01534052 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
NCT01650194 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924 ·Status: RECRUITING ·Phase: PHASE3
-
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
NCT02649855 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
NCT00658697 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06318273 ·Status: RECRUITING ·Phase: PHASE1
-
ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer
NCT03136640 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
NCT01288911 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
NCT02991911 ·Status: COMPLETED ·Phase: PHASE1
-
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
NCT00116142 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
NCT01734681 ·Status: WITHDRAWN ·Phase: PHASE2
-
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
NCT07219303 ·Status: RECRUITING ·Phase: NA
-
Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
NCT00104130 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01663415 ·Status: WITHDRAWN ·Phase: PHASE2
-
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
NCT00771017 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
NCT02111577 ·Status: COMPLETED ·Phase: PHASE3
-
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
NCT01911728 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
NCT01605227 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
NCT02065323 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01283373 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
NCT02124668 ·Status: COMPLETED ·Phase: PHASE2
-
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03456804 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
NCT02441517 ·Status: TERMINATED ·Phase: PHASE4